Prelude Capital Management’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-4,532
Closed -$421K 2497
2021
Q4
$421K Buy
+4,532
New +$299K 0.01% 1121
2021
Q1
Sell
-3,403
Closed -$261K 1924
2020
Q4
$261K Buy
3,403
+1,489
+78% +$112K 0.01% 980
2020
Q3
$143K Buy
1,914
+157
+9% +$10.5K 0.01% 786
2020
Q2
$111K Buy
+1,757
New +$96.7K 0.01% 918
2017
Q3
Sell
-3,400
Closed -$57K 1984
2017
Q2
$57K Sell
3,400
-6,140
-64% -$84.2K 0.01% 967
2017
Q1
$139K Buy
9,540
+6,170
+183% +$91.4K 0.01% 681
2016
Q4
$48K Buy
3,370
+720
+27% +$11.2K 0.01% 1060
2016
Q3
$46K Sell
2,650
-1,980
-43% -$32.8K ﹤0.01% 1066
2016
Q2
$79K Buy
4,630
+3,070
+197% +$54.9K 0.01% 845
2016
Q1
$31K Sell
1,560
-2,120
-58% -$34K ﹤0.01% 1051
2015
Q4
$70K Buy
+3,680
New +$75.1K 0.01% 945

Prelude Capital Management's ARNA Position: Q1 2022 in Review

Prelude Capital Management sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 4,532 shares — an estimated $421K sold.

Prelude Capital Management first reported a position in ARNA in Q4 2015 and held it in 11 quarters. The position peaked at $421K in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.

  • Prelude Capital Management reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
  • Prelude Capital Management sold 4,532 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $421K.
  • Prelude Capital Management first reported a position in Arena Pharmaceuticals Inc in Q4 2015 and held it in 11 quarters.
  • Prelude Capital Management's Arena Pharmaceuticals Inc position peaked at $421K in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.

Based on Prelude Capital Management's 13F filing for Q1 2022, filed 16 May 2022.